BioPharma Pharma Research
Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments
Data demonstrate diversity of vaccine and anti-infective portfolio and cutting-edge scientific approach to battling viral and bacterial infections P...
October 19, 2022 | News
The Grand Hamdan Award goes to two scientists in Australia
According to an official announcement made recently in Dubai, Prof. Ian Hector Frazer and the Late Dr. Jian Zhou are the winners o...
October 19, 2022 | News
Kira Pharmaceuticals Announces IND Approval from Chinese NMPA
Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today th...
October 17, 2022 | News
Menarini Silicon Biosystems's CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination
Menarini Silicon Biosystems (MSB), Inc. is announcing that the AMA has issued Current Procedural Terminology (CPT®) Proprietary Laboratory Analyse...
October 14, 2022 | News
New cell population identified in Alzheimer's Disease allows better targeting of macrophage populations in treatment of neurodegeneration
An Immunity research study has found that the previously identified disease associated microglia (DAM) population detected in murine Alzheimer’s dise...
October 11, 2022 | News
Cytiva strengthens cell line development with CEVEC acquisition
Viral vector manufacturing and cell line development are keystone technologies in the making of gene therapies 46 scientific experts based in Cologne, G...
October 06, 2022 | News
Astellas and Pantherna Enter into a New Technology Evaluation Agreement
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D., "Panthe...
October 04, 2022 | News
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the...
September 27, 2022 | News
Sciwind Biosciences and SynerK Enter into Research Partnership
The partnership combines Sciwind's expertise in disease biology and clinical development capabilities with SynerK's proprietary conjugate-based siRNA deliv...
September 27, 2022 | News
AAHRPP Accredits Five More Research Organizations, Including First in Japan
At its September meeting, AAHRPP's Council on Accreditation awarded full accreditation to: Adventist Health Glendale, Glendale, California, a hospi...
September 26, 2022 | News
SCG Cell Therapy To Establish Cell Therapy Pilot cGMP Manufacturing Facility And R&D Centre In Singapore
With the support of the Singapore Economic Development Board (EDB), the hub comprises a pilot manufacturing facility and an R&D centre. SCG expect...
September 21, 2022 | News
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®
CorLiCyte® is in development for the treatment of a number of serious conditions, with a first target indication of treating diabetic foot ulcer (...
September 19, 2022 | News
United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging ...
September 16, 2022 | News
Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients
First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...
September 14, 2022 | News
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
